Combination cannabinoid-phenylethanoid formulation for treatment of inflammation and methods related thereto

Abstract

The present invention describes cannabinoid formulations that combine cannabinoids, such as CBD, with other active agents within the phenylethanoid class of compounds, such as oleocanthal, which, in combination, provide synergistic anti-inflammatory effects. These combination preparations are capable of increasing anti-inflammatory effects when compared to each individual compound alone, and are further capable of delivery through a variety of administration routes.

What is claimed is: 
     
         1 . A composition for treatment of inflammatory conditions in an animal, said composition comprising:
 at least one cannabinoid; and   at least one phenylethanoid;   
       wherein said composition is capable of having an anti-inflammatory effect when administered to an animal, and 
       wherein the at least one phenylethanoid comprises oleocanthal. 
     
     
         2 . The composition of  claim 1 , wherein the molar ratio of the at least one cannabinoid and the at least one phenylethanoid is between 10:1 and 1:10. 
     
     
         3 . The composition of  claim 1 , wherein the molar ratio of the at least one cannabinoid and the at least one phenylethanoid is between 5:1 and 1:5. 
     
     
         4 . The composition of  claim 1 , wherein the molar ratio of the at least one cannabinoid and the at least one phenylethanoid is substantially 1:1. 
     
     
         5 . The composition of  claim 1 , wherein said composition is suitable for administration selected from a group consisting of: oral administration, topical administration, mucosal administration, pulmonary administration, subcutaneous administration, intravenous administration, intraperitoneal administration, suppository administration, and intramuscular administration. 
     
     
         6 . The composition of  claim 1 , wherein said composition is a formulation selected from a group consisting of: a tablet, capsule, spray, drop, solution, suspension, gel, ointment, lotion, cream, powder, transdermal patch, tampon, or a sponge. 
     
     
         7 . The composition of  claim 1 , wherein the at least one phenylethanoid is selected from the group consisting of: olive oil, oleocanthal, tyrosol, hydroxytyrosol, and combinations thereof. 
     
     
         8 . The composition of  claim 1 , wherein the cannabinoid is cannabidiol (CBD). 
     
     
         9 . The composition of  claim 1 , wherein the cannabinoid is selected from the group consisting of: cannabidiol (CBD), cannabidivarol (CBDV), cannabinol (CBN), cannabigerol (CBG), cannabivarol (CBV), cannabicyclol (CBL), tetrahydrocannabinol (THC), tetrahydrocannabinol-C4, (THC-C4), tetrahydrocannabivarin (THCV), 11-Hydroxy-49-tetrahydrocannabinol, (11-OH-THC), 11-nor-9-Carboxy-Δ9-tetrahydrocannabinol, and combinations thereof. 
     
     
         10 . A method for preparing a combination formulation having anti-inflammatory properties, the method comprising the steps of:
 providing at least one cannabinoid;   providing at least one phenylethanoid, wherein the at least one phenylethanoid comprises oleocanthal; and   
       combining the at least one cannabinoid and the at least one phenylethanoid to form a combination formulation; 
       wherein said combination formulation is capable of reducing inflammation in an animal administered said combination formulation. 
     
     
         11 . The method of  claim 10 , wherein a molar ratio of the at least one cannabinoid and the at least one phenylethanoid in the combination formulation is between 10:1 and 1:10. 
     
     
         12 . The method of  claim 10 , wherein a molar ratio of the at least one cannabinoid and the at least one phenylethanoid in the combination formulation is between 5:1 and 1:5. 
     
     
         13 . The method of  claim 10 , wherein a molar ratio of the at least one cannabinoid and the at least one phenylethanoid in the combination formulation is substantially 1:1. 
     
     
         14 . The method of  claim 10 , wherein said combination formulation is suitable for administration selected from a group consisting of: oral administration, topical administration, mucosal administration, pulmonary administration, subcutaneous administration, intravenous administration, intraperitoneal administration, suppository administration, and intramuscular administration. 
     
     
         15 . The method of  claim 10 , wherein said combination formulation is a formulation selected from the group consisting of: a tablet, capsule, spray, drop, solution, suspension, gel, ointment, lotion, cream, powder, transdermal patch, tampon, or a sponge. 
     
     
         16 . The method of  claim 10 , wherein the at least one phenylethanoid is selected from a group consisting of: olive oil, oleocanthal, tyrosol, hydroxytyrosol, and combinations thereof. 
     
     
         17 . The method of  claim 10 , wherein the cannabinoid is cannabidiol (CBD). 
     
     
         18 . The method of  claim 10 , wherein the cannabinoid is selected from the group consisting of: cannabidiol (CBD), cannabidivarol (CBDV), cannabinol (CBN), cannabigerol (CBG), cannabivarol (CBV), cannabicyclol (CBL), tetrahydrocannabinol (THC), tetrahydrocannabinol-C4, (THC-C4), tetrahydrocannabivarin (THCV), 11-Hydroxy-49-tetrahydrocannabinol, (11-OH-THC), 11-nor-9-Carboxy-Δ9-tetrahydrocannabinol, and combinations thereof.